Entities / Company
Plus Therapeutics.
biopharmaceutical company
- Reports this week
- 0
- Active events
- 0
- Connections
- 43
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
One to three months ago
Gone quiet
No new reports in 90+ days-
Plus Therapeutics filed a request to withdraw a resale registration statement with the Securities and Exchange Commission of Bangladesh.Speculative1 report
-
Plus Therapeutics received FDA clearance for REYOBIQTM and secured a research grant from the U.S. Department of Defense.Speculative1 report
-
Plus Therapeutics developed radiotherapeutics for glioblastoma and is headquartered in Houston.Speculative1 report
-
Plus Therapeutics is running a dose optimization trial for REYOBIQ™ in alignment with FDA's Project Optimus.Speculative1 report
-
Plus Therapeutics is receiving funding from the Cancer Prevention and Research Institute of Texas for a dose optimization trial.Some support2 reports
-
CNSide Diagnostics, LLC became a wholly-owned subsidiary of Plus Therapeutics on July 31, 2025.Some support6 reports
-
AI is changing healthcare and impacting drug discovery, involving Plus Therapeutics and Animation International.Some support2 reports
-
Plus Therapeutics shares lost 50.1% on August 15, 2025, compared to the S&P 500's 10% gain.Some support2 reports
-
Plus Therapeutics, a company, established its headquarters in Houston and its listing on the Nasdaq exchange on August 15, 2025.Some support2 reports
-
Plus Therapeutics is developing targeted radiotherapeutics for CNS cancers, testing the product REYOBIQ in the ReSPECT-LM trial.Some support1 report
-
Plus Therapeutics met the listing criteria requirements for Nasdaq on August 26, 2025.Some support1 report
-
Plus Therapeutics is participating in a conference hosted by H.C. Wainwright, where Sean Lee serves as VP of Equity Research and Marc H. Hedrick is President and CEO.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around Plus Therapeutics this week
News at the entities that move Plus Therapeutics most-
Geode Capital Management TransactionalGeode Capital Management increased its stake in Amgen stock and filed the disclosure with the SEC.Moves Plus Therapeutics
-
Cancer Prevention and Research Institute of Texas TransactionalBiodexa Pharmaceuticals PLC is seeking Orphan Drug designation from the EMA and received $20 million in grant funding from the Cancer Prevention and Research Institute of Texas.Moves Plus Therapeutics
-
UWM Holdings Corp filed an 8-K with the Securities and Exchange Commission (Bangladesh) on May 13, 2026.
Moves Plus Therapeutics
-
FDA StructuralGeneric medicine services are seeking approval for launch from the FDA.Moves Plus Therapeutics
-
Houston Shared contextOntario company turns woody biomass into coal replacement while TCEQ regulates site acquisition in Houston.Moves Plus Therapeutics
-
Kentucky Shared contextSilver Elephant Mining Corp., based in Vancouver and listed on the TSX, has optioned a project in Kentucky.Moves Plus Therapeutics
Connections
The 8 strongest of 43, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Geode Capital Management Transactional
Geode Capital Management increased its investment stake in Plus Therapeutics.
-
Cancer Prevention and Research Institute of Texas Transactional
The Institute provides grant funding and advance payments to Plus Therapeutics to accelerate research and development.
-
Michael Rosol Structural
Michael Rosol serves as the Chief Development Officer at Plus Therapeutics.
-
Plus Therapeutics is subject to formal regulatory requirements, including periodic financial reporting, mandated by the Securities and Exchange Commission (Bangladesh).
-
FDA Structural
The FDA provides regulatory oversight, designations, and approvals necessary for Plus Therapeutics' drug development.
-
Houston Shared context
Plus Therapeutics is headquartered in Houston, Texas.
-
Kentucky Shared context
No evidence links Plus Therapeutics to Kentucky. The only available snapshot concerns CNSide Diagnostics.
-
Ohio Shared context
No evidence found regarding the relationship between Plus Therapeutics and Ohio.
History
Events by the month they beganJune 2026
12 events- Plus Therapeutics filed a request to withdraw a resale registration statement with the Securities and Exchange Commission of Bangladesh.
- Plus Therapeutics received FDA clearance for REYOBIQTM and secured a research grant from the U.S. Department of Defense.
- Plus Therapeutics developed radiotherapeutics for glioblastoma and is headquartered in Houston.
- Plus Therapeutics is running a dose optimization trial for REYOBIQ™ in alignment with FDA's Project Optimus.
- Plus Therapeutics is receiving funding from the Cancer Prevention and Research Institute of Texas for a dose optimization trial.
- CNSide Diagnostics, LLC became a wholly-owned subsidiary of Plus Therapeutics on July 31, 2025.
- AI is changing healthcare and impacting drug discovery, involving Plus Therapeutics and Animation International.
- Plus Therapeutics shares lost 50.1% on August 15, 2025, compared to the S&P 500's 10% gain.
- Plus Therapeutics, a company, established its headquarters in Houston and its listing on the Nasdaq exchange on August 15, 2025.
- Plus Therapeutics is developing targeted radiotherapeutics for CNS cancers, testing the product REYOBIQ in the ReSPECT-LM trial.
- Plus Therapeutics met the listing criteria requirements for Nasdaq on August 26, 2025.
- Plus Therapeutics is participating in a conference hosted by H.C. Wainwright, where Sean Lee serves as VP of Equity Research and Marc H. Hedrick is President and CEO.